Rural Hospital System Demonstrates The Clinical Benefits Of Implementing Universal Hereditary Cancer Testing In Patients With Breast Cancer
Portfolio Pulse from Benzinga Newsdesk
Invitae (NYSE:NVTA), a medical genetics company, announced the results of a study on universal hereditary cancer genetic testing in breast cancer patients. The study, conducted with The Outer Banks Hospital in North Carolina, found that universal genetic testing improves patient outcomes and may reduce treatment costs. The study also found that 91.4% of patients underwent testing and received results that could aid in their healthcare journey.
October 12, 2023 | 8:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Invitae's study results could potentially boost the company's reputation and demand for its genetic testing services. The findings may also influence healthcare policies and practices, leading to increased usage of Invitae's services.
The study results highlight the effectiveness of Invitae's genetic testing services, which could increase demand for these services. Additionally, the findings may influence healthcare policies and practices, potentially leading to increased usage of Invitae's services.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100